Epigenomics AG (XTER:ECX)
€ 0.7 -0.088 (-11.17%) Market Cap: 490,000.00 Enterprise Value: -2.74 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 45/100

Q4 2019 and Preliminary Q1 2020 Epigenomics AG Earnings Call Transcript

Apr 29, 2020 / 01:00PM GMT
Release Date Price: €211.83 (+3.45%)
Operator

Good afternoon, ladies and gentlemen, and welcome to the Epigenomics AG conference call regarding the full year results 2019. (Operator Instructions) Let me now turn the floor over to your host, Mr. Frederic Hilke.

Frederic Hilke
Epigenomics AG - IR Officer

Thank you very much, Alexander. Hello and welcome to the conference call. Today, we will discuss Epigenomics 2019 full year financial results and Q1 2020 preliminary results. My name is Frederic Hilke. I'm the Investor Relations Manager for Epigenomics. With me on the phone is the CEO of Epigenomics AG, Greg Hamilton; as well as Jorge Garces, Chief Scientific Officer of Epigenomics AG.

Before I hand over the presentation to Greg, let me point out some legal information. The following presentation will contain expressly or implicitly certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot